SciClone Pharma launches $281m Hong Kong IPO
SciClone Pharmaceuticals, which manufactures a possible treatment for the coronavirus, hit the IPO market with a HK$2.18bn ($281.2m) offering on Friday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: